DV
Dividend Vision

BMKDF Stock — BioMark Diagnostics Inc

BioMark Diagnostics Inc (BMKDF)

Updated November 9, 2026.

BMKDF is a stock. Total return is -2.7% over the past 11.6 years, 325.8 points behind SPY at 323.1%.

BioMark Diagnostics Inc. develops early-stage cancer diagnostic technology, focusing on liquid biopsy metabolic panel assays for detecting lung cancer, glioblastoma, and breast cancer, with additional tests in development for gastrointestinal, prostate, and head and neck cancers. The company does not currently have an established distribution schedule. This security appeals primarily to investors seeking exposure to early-stage healthcare and diagnostic innovation rather than current income.

BMKDF performance versus SPY

Total return is -2.7% over the past 11.6 years, 325.8 points behind SPY at 323.1%. Over the past year its total return — price change plus distributions reinvested — is 45.4%. Its deepest 1-year drawdown was 36.1%.

WindowTotal returnCAGR
1M-10.9%—
3M-16.1%—
6M-20.4%—
YTD-2.1%—
1Y45.4%—
2Y CAGR—49.70%
3Y CAGR—20.40%
5Y CAGR—12.10%
Since inception 2015-03-23 · 11.6 years-2.7%-0.20%

BMKDF key facts

Asset type
Stock
Asset class
Equity
Inception date
03/23/2015
Distribution frequency
None
Last close
$0.32 (as of 2026-11-09)
Market cap
$34,298,314
Average volume
10,840
Beta
-0.387
Payout ratio
0.0%
EPS
-$0.02

How Dividend Vision calculates returns

Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

BMKDF risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 36.1%.

Who may consider BMKDF — and who may not

It is a weaker fit for investors who need monthly cash flow (BMKDF does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on BMKDF

Tagged: Healthcare.

Frequently asked questions

Does BMKDF pay monthly?

No. BMKDF does not currently distribute.

When does BMKDF pay a dividend?

BMKDF does not currently distribute.

How has BMKDF performed?

Total return is -2.7% over the past 11.6 years, 325.8 points behind SPY at 323.1%. Over the past year its total return — price change plus distributions reinvested — is 45.4%. Its deepest 1-year drawdown was 36.1%.

DividendVision analysis is generated from public SEC filing data and may not capture every change. Review the original filing for complete information.